Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL370 Target Snapshot

Human alphaherpesvirus 2 · ORGANISM · Human alphaherpesvirus 2

Back to Search Search this target Browse approvals Evidence Card
3,341Compounds
761Assays
16Approved Drugs
1,912.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Human alphaherpesvirus 2 as ChEMBL target CHEMBL370. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Human alphaherpesvirus 2
ORGANISM · Human alphaherpesvirus 2
As of 2026-09-14
ChEMBL target ID
CHEMBL370
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Human alphaherpesvirus 2 still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameHuman alphaherpesvirus 2
Target TypeORGANISM
OrganismHuman alphaherpesvirus 2
ChEMBL ↗ NCBI Taxonomy ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelHuman alphaherpesvirus 2
UniProt AccessionN/A

Human alphaherpesvirus 2

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Human alphaherpesvirus 2.

Review nameHuman alphaherpesvirus 2
OrganismHuman alphaherpesvirus 2
Clinical Profile

Clinical Phase Distribution

16
Approved
5
Phase III
5
Phase II
4
Phase I
Assay Mix

Activity Type Distribution

IC50437.0
KI1.0
EC501,474.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL346387 10.77 IC50 0.017 Preclinical
CHEMBL484 10.62 IC50 0.024 Clinical
CHEMBL504793 10.48 IC50 0.033 Preclinical
CHEMBL5187288 10.3 IC50 0.05 Preclinical
CHEMBL301240 10.28 IC50 0.05263 Preclinical
CHEMBL298845 10.04 IC50 0.09091 Preclinical
CHEMBL356437 9.92 IC50 0.12 Preclinical
CHEMBL358153 9.92 IC50 0.12 Preclinical
CHEMBL59520 9.58 IC50 0.2632 Preclinical
CHEMBL57548 9.54 IC50 0.2857 Preclinical
Distribution

pChEMBL Value Distribution

95
5.0
111
5.5
98
6.0
68
6.5
45
7.0
40
7.5
22
8.0
29
8.5
7
9.0
4
9.5
pChEMBL
Approved Drugs

Approved Drugs

ADEFOVIR DIPIVOXIL
CHEMBL922
Approved 2002
Properties Compare Identifier
PENCICLOVIR
CHEMBL1540
Approved 1996
Properties Compare Identifier
CIDOFOVIR
CHEMBL5314375
Approved 1996
Properties Compare Identifier
GANCICLOVIR
CHEMBL182
Approved 1989
Properties Compare Identifier
ACYCLOVIR
CHEMBL184
Approved 1982
Properties Compare Identifier
CICLOPIROX
CHEMBL1413
Approved 1982
Properties Compare Identifier
Assay Landscape

Assay Landscape

761
Total Assays
527
Tested Compounds
2
Assay Types
Functional — 754 assays, 527 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 736 478 6.0
cell-based format 17 49 5.8
assay format 1 0 —
ADME — 7 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 7 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine